Mestag Therapeutics, a biotech company harnessing new insights into fibroblast-immune interactions, announced that it has entered into a license and collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify novel targets for the development of therapies against inflammatory diseases. Mestag will employ its Reversing Activated Fibroblast Technology (RAFT) platform to identify novel drug targets. MSD has the option to license one or more targets and will be responsible for the discovery, development and commercialization of resulting therapeutics.